Mylan-Upjohn merger filings contemplate coronavirus impact

Mylan NV and Upjohn have added the potential impact of coronavirus onto its risk factors ahead of the merger between the two companies sometime later this year. The merger will create Viatris, a publicly traded company based in the United States that will be led by Mylan’s Robert J. Coury as executive chairman and Upjohn’s Michael Goettler as CEO. It will combine Mylan (Nasdaq: MYL) strengths in generic and other meds with Upjohn’s well-known brands . Upjohn, which is until the merger a division…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news